Canton Strategic Holdings (CNTN) Income from Continuing Operations (2021 - 2026)
Canton Strategic Holdings posted quarterly Income from Continuing Operations of 47343197.0 for Q1 2026, down 1762.66% year-on-year from 2847444.25 in Q1 2025, and down 1939.47% on a QoQ basis from 2321353.0 in Q4 2025.
Canton Strategic Holdings (CNTN) has 6 years of Income from Continuing Operations data on file, last reported at 47343197.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 1762.66% year-over-year to 47343197.0; the trailing twelve-month figure through Mar 2026 stood at 53621541.0 (down 330.72% YoY), and the FY2025 full-year result was 35916250.0, down 194.45% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 47343197.0, down from 2321353.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 1636854.0 in Q2 2022 and bottomed at 47343197.0 in Q1 2026.
- The 5-year median for Income from Continuing Operations is 2325057.0 (2024), against an average of 5065841.0.
- The widest annual swing landed in 2025, when Income from Continuing Operations soared 44.63%; it then plunged 1762.66% in 2026.
- A 5-year view of Income from Continuing Operations shows it stood at 1757682.0 in 2022, then slumped by 40.74% to 2473777.0 in 2023, then sank by 53.08% to 3786758.0 in 2024, then surged by 38.7% to 2321353.0 in 2025, then tumbled by 1939.47% to 47343197.0 in 2026.
- The last three Income from Continuing Operations figures came in at 47343197.0 (Q1 2026), 2321353.0 (Q4 2025), and 2101838.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Canton Strategic Holdings | 643.89 Mn | 602.36 Mn | - | -47.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -47.34 Mn |
| Dec 31, 2025 | -2.32 Mn |
| Sep 30, 2025 | -2.10 Mn |
| Jun 30, 2025 | -1.86 Mn |
| Mar 31, 2025 | -2.54 Mn |
| Dec 31, 2024 | -3.79 Mn |
| Sep 30, 2024 | -3.80 Mn |
| Jun 30, 2024 | -2.33 Mn |
| Mar 31, 2024 | -2.26 Mn |
| Dec 31, 2023 | -2.47 Mn |
| Sep 30, 2023 | -1.82 Mn |
| Jun 30, 2023 | -2.34 Mn |
| Mar 31, 2023 | -2.69 Mn |
| Dec 31, 2022 | -1.76 Mn |
| Sep 30, 2022 | -2.13 Mn |
| Jun 30, 2022 | -1.64 Mn |
| Mar 31, 2022 | -2.95 Mn |
| Dec 31, 2021 | -359,593.00 |
| Sep 30, 2021 | -777,113.00 |
| Jun 30, 2021 | -1.29 Mn |
| Mar 31, 2021 | -1.62 Mn |